Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

N-Glycolyl GM3 cancer vaccine - Center of Molecular Immunology/Recombio

Drug Profile

N-Glycolyl GM3 cancer vaccine - Center of Molecular Immunology/Recombio

Alternative Names: CIMAVaxG vaccine; N-glicolil GM3/VSSP; N-Glycolyl GM3/Vssp vaccine; N-glycolyl therapeutic vaccine; N-GlycolylGM3/VSSP/Montanide-ISA-51-vaccine; NGcGM3/VSSP vaccine

Latest Information Update: 30 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Center of Molecular Immunology
  • Developer Center of Molecular Immunology; Recombio
  • Class AIDS vaccines; Cancer vaccines; Conjugate vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Breast cancer
  • Phase II Malignant melanoma

Most Recent Events

  • 13 Dec 2017 Center of Molecular Immunology plans a clinical trial in Non-small cell lung cancer (Combination with Nimotuzumab, Late-stage disease) in Cuba (SC) (RPCEC00000270)
  • 09 Jan 2017 Center of Molecular Immunology plans a phase I/II trial in Small cell lung cancer in Cuba (RPCEC00000224)
  • 16 Dec 2016 Center of Molecular Immunology plans a phase II/III trial in Breast cancer (Combination therapy, First-line therapy, Metastatic disease) in Cuba (SC) (RPCEC00000220)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top